FDA rejects Regenxbio's Hunter syndrome gene therapy
FDA拒绝Regenxbio的Hunter综合征基因治疗

The FDA has rejected Regenxbio’s gene therapy for a serious inherited disease called Hunter syndrome in a decision that could reverberate to other rare disease drugmakers as well.
美国食品药品监督管理局(FDA)已拒绝Regenxbio针对一种名为亨特综合征的严重遗传性疾病的基因疗法，此举可能也会波及其他罕见病药企。